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Among these patients with newly diagnosed advanced gastric cancer, 58% undergo surgery while for those with incurable, unresectable, advanced, or metastatic disease, chemotherapy is the only beneficial treatment option.
G 5-Fluorouracil (5-FU) is considered the most active single agent and is used extensively for the treatment of gastric cancer.
2-4
G In a randomized phase III trial (ML17032), the oral fluoropyrimidine capecitabine (Xeloda ® ) in combination with cisplatin (XP) was found to be a safe and effective alternative to i.v. 5-FU plus cisplatin (FP) in previously untreated patients with advanced or metastatic gastric cancer (AGC).
5
G Trial results showed that XP is non-inferior to FP for both progression-free and overall survival, with a superior overall response rate for XP. G A cost-minimization analysis was undertaken by applying clinical outcomes and medical resource utilization (MRU) retrieved from the phase III trial by Kang et al.
G Study design is shown in Figure 1 : -comparators: capecitabine + cisplatin (XP) vs.
5-FU + cisplatin (FP).

Study outcomes
G A trend toward superior progression-free survival (PFS) was observed in the XP arm (median PFS 5.6 months for XP vs.
months for FP).
G Compared with FP, administration of XP required fewer consultations per patient (5.2 for XP vs. 22.8 for FP) ( Table 1) .
Cost measures
G In order to obtain the local Taiwan cost data for MRU, direct medical costs associated with trial-based MRU were based on Taiwan's National Health Insurance (TW NHI) Fee Schedule for Medical Services and Reference List for Drugs 2007 (Tables 2 and 3) . 6, 7 G Other costs associated with treatment were estimated by an expert panel survey conducted among 12 medical oncologists. 8, 9 Respondents were asked to indicate the appropriate level of MRU, including frequency of outpatient visits, laboratory examinations, and hospitalizations; procedure carried out; and drug administration costs for the management of AGC and its complications. 
Adverse events
G The adverse events (AEs) considered in the analysis were the most common grade 3/4 AEs.The cost of AE treatment differs when prices are applied to the frequency of each AE (Table 4) .
Cost-minimization analysis
G The total drug and administration cost for XP is NT$78,563 and for FP is NT$165,914 (Table 6 ; Figure 2 ).
G AE profiles were similar for XP and FP, while the costs associated with grade 3/4 AE management were slightly lower (NT$958) in the XP arm (Table 6 ; Figure 2 ).
G Overall, the total cost of XP is NT$87,351 (US$2,687) lower than that of FP ( Table 6 ), proving that XP is a cost-saving solution compared with FP in the treatment of AGC in Taiwan.
RESULTS
G Chemotherapy drug cost was estimated to be higher (NT$55,511) in the XP arm (Table 5 ).
G However, these cost increments were offset by differences for chemotherapy administration costs (NT$141,904) between the two arms ( Table 5) .
G This is a result of FP needing repeated doctor visits for monitoring and i.v. infusion vs. capecitabine being an orally administered drug. 
Sensitivity analyses
G One-way sensitivity analyses were performed on key model parameters by varying the input values by ±10% and ±20%. XP remained cost-saving under these one-way sensitivity analyses (Table 7) . 
